Valuation dashboard for Fate Therapeutics, Inc. (FATE) with P/E N/A, P/B 1.96, EV/EBITDA -2.84 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Analysis Summary
Fate Therapeutics, Inc. reported revenue of $6.6M in the most recent fiscal year, growing at a 5-year CAGR of -26.7%.
Trailing-twelve-month margins: gross margin -343.0%, operating margin -20.6%, net margin -19.4%.
At the current price of $2.44, FATE has negative trailing earnings (P/E not meaningful) and an ROE of -65.08%. Market capitalisation stands at $284M.
Balance sheet quality for FATE: current ratio of 5.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | -2.84 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | $284M | 1.96 | -65.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.44 |
| Market Cap | $284M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -65.08% |
| Return on Invested Capital | -57.47% |
| Return on Assets | -48.44% |
| Gross Margin | -343.01% |
| Operating Margin | -2058.08% |
| Net Margin | -1941.09% |
Related companies: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of FATE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks